Royalty Report: Drugs, Cancer, Therapeutic – Collection: 25940

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 25940

License Grant
An Australian Company signed a License for the clinical development, marketing and distribution of BrachySil in China. Under the terms of the License, we will manufacture BrachySil and Licensee will be responsible for clinical development, securing regulatory approval, marketing and distribution in China and Hong Kong. We will retain manufacturing rights for BrachySil under the License.
License Property
BrachySil, the company's lead BioSilicon application, is a targeted oncology product, which is presently in Phase II clinical trials for the treatment of both primary liver cancer and pancreatic cancer.

The technology company is about half way through U.S. regulatory testing of its modified silicon product BioSilicon that allows tiny pieces of radioactive material to be directly injected into primary liver tumours, as opposed to traditional radiotherapy that involves hitting a broader area with radiation.

Field of Use
“Licensed Field” 32P BioSilicon microparticles for use as a radiotherapy agent for the treatment or monitoring of solid cancerous tumours, including the primary tumour and metastases, which can be applied

i) interstitially within a cancerous tumour;

ii) into a resection cavity after surgical removal of a cancerous tumour;

iii) into the peritoneal cavity; or

iv) via the vasculature ( to the extent it becomes technically feasible).

IPSCIO Record ID: 7473

License Grant
The Licensee acquired an exclusive, worldwide, royalty-bearing License for the development of BrachySil.
License Property
BrachySil is a BioSilicon product candidate for the treatment of pancreatic and other types of cancer. The Licensee has the right to terminate its License upon 60 days prior written notice. Research and DevelopmentOur clinical and pre-clinical research programs primarily consist of ophthalmic applications of our technology systems.

IPSCIO Record ID: 1054

License Grant
Licensor hereby grants an exclusive, non-transferable, sublicensable right and license, solely in the Licensed Territory and the Licensed Field of Use, (i) under the Patent Rights and the Licensee Patent Rights improvements to make, have made, sell, lease, offer for sale, and import the Licensed Products, and (ii) to use the Licensor Information solely in connection with the Licensed Products.
License Property
Patent Rights PCT/US04/019337 Microparticles for Micro-arterial Imaging and Radiotherapy.

Its intended use is as a means of micro-arterial brachytherapy in the treatment of soft tissue cancer tumors in the liver. Soft tissue tumors are connected to the blood supply and this kind of therapy is administered through the blood supply system. Soft tissue tumors are among the most difficult forms of cancer to treat.

Field of Use
Licensed Field of Use shall mean the human healthcare field.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.